

**Editor**

Tore K Kvien

**Associate Editors**

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 9.111

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2013 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.  
Register using this QR code.

**Editorial**

- 1433** Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples  
*B Combe, R van Vollenhoven*

**Review**

- 1436** Drug therapy in undifferentiated arthritis: a systematic literature review  
*K V C Wevers-de Boer, L Heimans, T W J Huizinga, C F Allaart*

**Clinical and epidemiological research**

- 1445** Efficacy and safety of mavrilumab in subjects with rheumatoid arthritis



*G R Burmester, M E Weinblatt, I B McInnes, D Porter, O Barbarash, M Vautin, I Szombati, E Esfandiari, M A Sleeman, C D Kane, G Cavet, B Wang, A Godwood, F Magrini, for the EARTH Study Group*

- 1453** A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate



*M C Genovese, E Lee, J Satterwhite, M Veenhuizen, D Disch, P-Y Berclaz, S Myers, G Sides, O Benichou*

- 1461** Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors



*M C Genovese, R M Fleischmann, M Greenwald, J Satterwhite, M Veenhuizen, L Xie, P-Y Berclaz, S Myers, O Benichou*

- 1469** Long-term safety of pegloticase in chronic gout refractory to conventional treatment



*M A Becker, H S B Baraf, R A Yood, A Dillon, J Vázquez-Mellado, F D Oteri, D Khanna, J S Sundry*

- 1475** Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis



*E Pathan, S Abraham, E Van Rossen, R Withrington, A Keat, P J Charles, E Paterson, M Chowdhury, C McClinton, P C Taylor*

- 1481** Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis



*G Espigol-Frigolé, M Corbera-Bellalta, E Planas-Rigol, E Lozano, M Segarra, A García-Martínez, S Prieto-González, J Hernández-Rodríguez, J M Grau, M U Rahman, M C Cid*

- 1488** Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks



*T Takeuchi, M Harigai, Y Tanaka, H Yamanaka, N Ishiguro, K Yamamoto, N Miyasaka, T Koike, M Kanazawa, T Ōba, T Yoshinari, D Baker, the GO-MONO study group*

- 1496** Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients



*R F van Vollenhoven, P Emery, C O Bingham III, E C Keystone, R M Fleischmann, D E Furst, N Tyson, N Collinson, P B Lehane*

- 1503** Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study  
*P M Miettunen, A Pistorio, E Palmisani, A Ravelli, E Silverman, S Oliveira, M Alessio, R Cuttica, D Mihaylova, G Espada, S Pasic, A Insalaco, S Ozen, O Porras, F Sztajnbock, D Lazarevic, A Martini, N Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO)*

- 1510** Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behçet's disease  
*Y J Lee, Y Horie, G R Wallace, Y S Choi, J A Park, J Y Choi, R Song, Y-M Kang, S W Kang, H J Baek, N Kitachi, A Meguro, N Mizuki, K Namba, S Ishida, J Kim, E Niemczyk, E Y Lee, Y W Song, S Ohno, E B Lee*

- 1517** Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population



*S M M Verstappen, M Lunt, R N Luben, J Chipping, T Marshall, K-T Khaw, N Wareham, W G Dixon, I N Bruce, D P M Symmons*

- 1524** Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings

*K Thorlund, E Druyts, J A Aviña-Zubietta, P Wu, E J Mills*

- 1536** Predictors of preterm birth in patients with mild systemic lupus erythematosus

*M E B Clowse, D J Wallace, M Weisman, A James, L G Criscione-Schreiber, D S Pisetsky*

- 1540** MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis

*A Krabben, W Stomp, D M F M van der Heijde, J A B van Nies, J L Bloem, T W J Huizinga, M Reijnen, A H M van der Helm-van Mil*

- 1545** Tendon involvement in the feet of patients with gout: a dual-energy CT study

*N Dalbeth, R Kalluru, O Aati, A Horne, A J Doyle, F M McQueen*

**MORE CONTENTS ►**

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



COPE

COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)



EQUATOR

network



RECYCLE

When you have finished with this please recycle it

**Basic and translational research**

- 1549** Foxp3<sup>+</sup> Helios<sup>+</sup> regulatory T cells are expanded in active systemic lupus erythematosus  
*T Alexander, A Sattler, L Templin, S Kohler, C Groß, A Meisel, B Sawitzki, G-R Burmester, R Arnold, A Radbruch, A Thiel, F Hiepe*
- 1559** Epstein–Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis  
*C Croia, B Serafini, M Bombardieri, S Kelly, F Humby, M Severa, F Rizzo, E M Coccia, P Migliorini, F Aloisi, C Pitzalis*
- 1569** The novel cytokine interleukin-36 $\alpha$  is expressed in psoriatic and rheumatoid arthritis synovium  
*S Frey, A Derer, M-E Messbacher, D L P Baeten, S Bugatti, C Montecucco, G Schett, A J Hueber*
- 1575** Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling  
*A Distler, L Deloch, J Huang, C Dees, N-Y Lin, K Palumbo-Zerr, C Beyer, A Weidemann, O Distler, G Schett, J H W Distler*

**Letters**

- 1581** Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis  
*J E Paramarta, T F Heijda, D L Baeten*
- 1583** Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study  
*N Dalbeth, B Pool, S Yip, J Cornish, R Murphy*
- 1584** Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis  
*F Alberici, A Palmisano, M L Urban, F Maritati, E Oliva, L Manenti, S Ferretti, R Cobelli, C Buzio, A Vaglio*
- 1586** Independent relationship between circulating resistin concentrations and endothelial activation in rheumatoid arthritis  
*P H Dessen, G R Norton, A J Woodiwiss, A Solomon*